|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
Valuation Estimation |
EPS (Current/Estimated)
-1.20/-1.91
|
Enterprise Value
1.09B
|
Balance Sheet |
Book Value Per Share
0.42
|
Cash Flow |
Cash Flow Yield
--
|
Income Statement |
Total Revenue
1.70M
|
Operating Revenue Per Share
0.02
|
Industry Comparison
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
Quotes are at least 15-min delayed:2024/05/16 08:06 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
|
|||
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3,AUTO5, AUTO6, AUTO7 & AUTO8. |